CD4 and neoplasm: Our current study demonstrates that Uro A treatment can effectively reduce primary tumor burden in a T cell–dependent manner, decrease immunosuppressive tumor-associated macrophages (TAM), and significantly increase the infiltration of CD4+ and CD8+ T cells with a memory-like phenotype in the TME.